{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:09:50Z","timestamp":1778875790374,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea","award":["HI13C2096, HI14C0072, HI14C2750, and HI14C3418"],"award-info":[{"award-number":["HI13C2096, HI14C0072, HI14C2750, and HI14C3418"]}]},{"name":"Samsung Medical Center","award":["GF01140111"],"award-info":[{"award-number":["GF01140111"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable \u201cprecision medicine,\u201d wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancer-related genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic\/biliary tract cancer, 67 sarcoma\/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12%) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44%) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0020","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T01:20:17Z","timestamp":1499908817000},"page":"1169-1177","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials"],"prefix":"10.1093","volume":"22","author":[{"given":"Seung Tae","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gasteroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"},{"name":"Departments of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayoung K.D.","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Genome Institute, Samsung Medical Center, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soomin","family":"Ahn","sequence":"additional","affiliation":[{"name":"Innovative Cancer Medicine Institute, Samsung Cancer Center, Seoul, Korea"},{"name":"Departments of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Yun","sequence":"additional","affiliation":[{"name":"Samsung Genome Institute, Samsung Medical Center, Seoul, Korea"},{"name":"Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Genome Institute, Samsung Medical Center, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics Harvard Medical School, Boston, Masachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Cheol","family":"Kim","sequence":"additional","affiliation":[{"name":"Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Sung","family":"Sohn","sequence":"additional","affiliation":[{"name":"Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Il","family":"Choi","sequence":"additional","affiliation":[{"name":"Departments of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Ho","family":"Cho","sequence":"additional","affiliation":[{"name":"Departments of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Heo","sequence":"additional","affiliation":[{"name":"Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooil","family":"Kwon","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyuk","family":"Lee","sequence":"additional","affiliation":[{"name":"Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Hoon","family":"Min","sequence":"additional","affiliation":[{"name":"Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung No","family":"Hong","sequence":"additional","affiliation":[{"name":"Innovative Cancer Medicine Institute, Samsung Cancer Center, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong-Yang","family":"Park","sequence":"additional","affiliation":[{"name":"Samsung Genome Institute, Samsung Medical Center, Seoul, Korea"},{"name":"Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea"},{"name":"Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,7,12]]},"reference":[{"key":"2021122508231232200_R1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrg2841","article-title":"Advances in understanding cancer genomes through second-generation sequencing","volume":"11","author":"Meyerson","year":"2010","journal-title":"Nat Rev Genet"},{"key":"2021122508231232200_R2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508231232200_R3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMp1501964","article-title":"Cutting the gordian helix\u2013regulating genomic testing in the era of precision medicine","volume":"372","author":"Lander","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508231232200_R4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2014.18145","article-title":"Genetic testing and FDA regulation: Overregulation threatens the emergence of genomic medicine","volume":"313","author":"Evans","year":"2015","journal-title":"JAMA"},{"key":"2021122508231232200_R5","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1056\/NEJMsr1501194","article-title":"The FDA and genomic tests\u2013getting regulation right","volume":"372","author":"Evans","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508231232200_R6","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility","volume":"33","author":"Robson","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508231232200_R7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccr.2010.11.033","article-title":"Alk inhibition for non-small cell lung cancer: From discovery to therapy in record time","volume":"18","author":"Gerber","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122508231232200_R8","doi-asserted-by":"crossref","first-page":"e111693","DOI":"10.1371\/journal.pone.0111693","article-title":"High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"key":"2021122508231232200_R9","doi-asserted-by":"crossref","first-page":"e38892","DOI":"10.1371\/journal.pone.0038892","article-title":"High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"2021122508231232200_R10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer","year":"2014","journal-title":"Nature"},{"key":"2021122508231232200_R11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer","year":"2012","journal-title":"Nature"},{"key":"2021122508231232200_R12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature15819","article-title":"Patient-centric trials for therapeutic development in precision oncology","volume":"526","author":"Biankin","year":"2015","journal-title":"Nature"},{"key":"2021122508231232200_R13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/498146a","article-title":"'Master protocol' aims to revamp cancer trials","volume":"498","author":"Ledford","year":"2013","journal-title":"Nature"},{"key":"2021122508231232200_R14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.drudis.2015.10.005","article-title":"Precision medicine in oncology drug development: A pharma perspective","volume":"20","author":"Hollingsworth","year":"2015","journal-title":"Drug Discov Today"},{"key":"2021122508231232200_R15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/bjc.2014.211","article-title":"Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: Results of the feasibility part of the SHIVA trial","volume":"111","author":"Le Tourneau","year":"2014","journal-title":"Br J Cancer"},{"key":"2021122508231232200_R16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (safir01\/unicancer)","volume":"15","author":"Andre","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122508231232200_R17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.10050","article-title":"Molecular screening for cancer treatment optimization (moscato 01) in pediatric patients: First feasibility results of a prospective molecular stratification trial","author":"Geoerger","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122508231232200_R18","doi-asserted-by":"crossref","first-page":"33358","DOI":"10.18632\/oncotarget.5188","article-title":"The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: Prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"2021122508231232200_R19","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122508231232200_R20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.14348\/molcells.2015.0078","article-title":"Identification and clinical implications of novel MYO15A mutations in a non-consanguineous Korean family by targeted exome sequencing","volume":"38","author":"Chang","year":"2015","journal-title":"Mol Cells"},{"key":"2021122508231232200_R21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","article-title":"Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil","volume":"145","author":"Lei","year":"2013","journal-title":"Gastroenterology"},{"key":"2021122508231232200_R22","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/bjc.2014.341","article-title":"The aurora initiative for metastatic breast cancer","volume":"111","author":"Zardavas","year":"2014","journal-title":"Br J Cancer"},{"key":"2021122508231232200_R23","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(05)66379-9","article-title":"Compared to what? Finding controls for case-control studies","volume":"365","author":"Grimes","year":"2005","journal-title":"Lancet"},{"key":"2021122508231232200_R24","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508231232200_R25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1586\/14737159.2015.992417","article-title":"Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme","volume":"15","author":"Lindsay","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"2021122508231232200_R26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdw073","article-title":"Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials","volume":"27","author":"Overman","year":"2016","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/10\/1169\/41913493\/oncolo_22_10_1169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/10\/1169\/41913493\/oncolo_22_10_1169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:24:16Z","timestamp":1640420656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/10\/1169\/6444579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,12]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,7,12]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0020","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,1]]},"published":{"date-parts":[[2017,7,12]]}}}